Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.45 |
| ▸ | BRD2 | P25440 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 5/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624454 | 1.00 | BRD4 (0.45) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL5624761 | 0.94 | BRD4 (0.46) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL5624756 | 0.94 | BRD4 (0.46) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL5428640 | 0.89 | BRD4 (0.45) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL5428644 | 0.89 | BRD4 (0.45) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL6319740 | 0.87 | KMT2A (0.41) | KMT2ATSHRMEN1 | |
| SCHEMBL6319738 | 0.87 | KMT2A (0.41) | KMT2ATSHRMEN1 | |
| SCHEMBL6750851 | 0.86 | BRD4 (0.49) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL6988928 | 0.86 | BRD4 (0.49) | BRD4BRD2AURKAAURKBKMT2A | |
| SCHEMBL5424347 | 0.86 | BRD4 (0.49) | BRD4BRD2AURKAAURKBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166615-B2 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7160901-B2 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-09 | — | — | US | disclosed |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | BRD4 1145/4885BRD2 1996/4885AURKA 98/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | BRD4 1145/4885BRD2 1996/4885AURKA 98/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | BRD4 1082/4885BRD2 2405/4885AURKA 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.